Heart rhythm · 2025
Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy.
Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oikawa Jun, Fukaya Hidehira, Kanaoka Koshiro, Niwano Shinichi, Miyamoto Koji, Iwanaga Yoshitaka, Iwasaki Yu-Ki, Nagashima Koichi, Masuda Masaharu, Yamashita Seigo, Nakamura Kohki, Satomi Kazuhiro, Takatsuki Seiji, Inoue Koichi, Kusano Kengo, Yamane Teiichi, Tada Hiroshi, Shimizu Wataru
Аннотация
BACKGROUND: Catheter ablation (CA) is an effective rhythm control therapy for atrial fibrillation (AF). Recent advancements have improved its efficacy and safety. From 2022 to 2024, guidelines in the United States, Japan, and Europe classify CA as a Class I recommendation for paroxysmal AF (PAF) as a first-line therapy. Previously, CA was recommended as Class I only for the patient refractory to drug therapy. Despite these updates, direct comparative studies between first-line CA and second-line CA remain limited.
OBJECTIVE: This study aimed to evaluate the efficacy and safety of CA as first-line versus second-line therapy using data from the Japan Nationwide Ablation (J-AB) registry.
METHODS: We analyzed patients with PAF who underwent CA from 2017 to 2020 in the J-AB registry. Patients were categorized into a First-line group (CA without prior antiarrhythmic drug [AAD]) and a Second-line group (CA following AAD failure). Efficacy was assessed by recurrence of atrial tachyarrhythmia within 1 year after a 90-day blanking period. Safety was evaluated based on major complications, including severe bleeding, stroke, and gastrointestinal disorders.
RESULTS: Among 5011 patients (median age 69 years, 35% were women), baseline characteristics were similar between groups except for beta-blocker use. Recurrence rates were comparable (10.0% overall; log-rank P = .49), and Cox regression showed no significant difference in efficacy (adjusted hazard ratio: 1.06, 95% confidence interval: 0.88-1.28, P = .55). Safety outcomes were also similar.
CONCLUSION: First-line CA for PAF demonstrated similar efficacy and safety to second-line CA within 1 year. The registry was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN 000028288) and ClinicalTrials.gov (NCT03729232).
OBJECTIVE: This study aimed to evaluate the efficacy and safety of CA as first-line versus second-line therapy using data from the Japan Nationwide Ablation (J-AB) registry.
METHODS: We analyzed patients with PAF who underwent CA from 2017 to 2020 in the J-AB registry. Patients were categorized into a First-line group (CA without prior antiarrhythmic drug [AAD]) and a Second-line group (CA following AAD failure). Efficacy was assessed by recurrence of atrial tachyarrhythmia within 1 year after a 90-day blanking period. Safety was evaluated based on major complications, including severe bleeding, stroke, and gastrointestinal disorders.
RESULTS: Among 5011 patients (median age 69 years, 35% were women), baseline characteristics were similar between groups except for beta-blocker use. Recurrence rates were comparable (10.0% overall; log-rank P = .49), and Cox regression showed no significant difference in efficacy (adjusted hazard ratio: 1.06, 95% confidence interval: 0.88-1.28, P = .55). Safety outcomes were also similar.
CONCLUSION: First-line CA for PAF demonstrated similar efficacy and safety to second-line CA within 1 year. The registry was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN 000028288) and ClinicalTrials.gov (NCT03729232).